Sickle cell disease: How new technologies are transforming patient lives

Originally presented: Sept. 12, 2024

Presentation Recording Coming Soon

Overview

In this “Future Direction of Laboratory Medicine” webinar, Maggie DiGuardo, M.D., and Justin Juskewitch, M.D., Ph.D., will review the current knowledge regarding sickle cell disease from its genetic cause to the myriads of effects it can have for affected individuals. Through the lens of a clinical case study, they will describe the current treatment modalities available for long-term management of patients with sickle cell disease. The presenters will then explore the new gene therapy-based treatments for sickle cell disease and the clinical trials that supported the recent FDA approval.

Presenters

Maggie DiGuardo, M.D.

Assistant Professor of Laboratory Medicine and Pathology
Division of Transfusion Medicine
Mayo Clinic, Rochester, Minnesota

Justin Juskewitch, M.D., Ph.D.

Assistant Professor of Laboratory Medicine and Pathology
Division of Transfusion Medicine
Mayo Clinic, Rochester, Minnesota

Learning objectives

Upon completion of this activity, participants should be able to:

  • Describe the prevalence and pathophysiology of sickle cell disease.
  • Summarize current clinical management approaches with associated challenges and limitations. 
  • State new treatment modalities and potential patient impact.

Intended audience

This webinar is appropriate for laboratory leaders, healthcare providers, and other laboratory personnel who are interested in innovations and the future direction of lab medicine. 

Credit

The following types of credit are offered for this event:

ASCLS P.A.C.E.®

Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.

State of Florida

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General (Hematology) credit. This program has been approved for 1.0 contact hour.

To obtain credit


1. Register for and participate in the program.

2. Complete the evaluation that will be sent to you after the program.

3. Generate and print your certificate(s).


Level of instruction for this program is intermediate.


Faculty disclosure


Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

Questions

Contact us: mcleducation@mayo.edu

MCL Education

This post was developed by our Education and Technical Publications Team.